Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel
19 April 2023
Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region. This panel is a key component of our comprehensive DefineMBC blood biopsy for metastatic breast cancer.
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
18 April 2023
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors.
binx health Further Expands Commercial Team in Support of Point-of-Care National Rollout
17 April 2023
binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announces the Company is expanding its commercial organization in response to a growing demand for its FDA-cleared, CLIA-waived, point-of-care (POC) testing platform for chlamydia (CT) and gonorrhea (NG). The binx io is the only molecular POC platform of its kind proven to detect CT and NG in male urine and female vaginal swab samples in about 30 minutes with performance equivalent to the central laboratory.
Epic Sciences raises $24m in series G financing to continue funding commercialization of DefineMBC
14 April 2023
Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. The company will use the capital from this additional round of private investment to fund the commercial infrastructure required to commercialize the three component tests of DefineMBC, which together provide a comprehensive blood-based biopsy result for patients with metastatic breast cancer.
22 March 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appoMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut syndrome (LGS).intment of Christine Silverstein to its Board of Directors and Audit Committee.
07 March 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.
07 March 2023
binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, is supporting the Elton John AIDS Foundation to increase access to testing for HIV, sexually transmitted infections (STIs), and pre-exposure prophylaxis (PrEP) on a national scale. Self-collection kits will be made available to consumers through an Elton John AIDS Foundation custom branded website with cash pay and insurance bill options for at-home access to all essential components of a comprehensive PrEP and HIV/STI screening program: HIV, HPV, syphilis, hepatitis C, hepatitis B, trichomoniasis, chlamydia, gonorrhea, and creatinine.
01 March 2023
Birmingham AIDS Outreach (BAO), Alabama’s leading advocacy organization for people living with HIV/AIDS, and binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, launch the Sassy Little Box program to enable access to HIV and sexually transmitted infection (STI) testing and care at the community level. The Sassy Little Box program aims to serve at-risk communities throughout the greater Birmingham area and leverages years of partnership between BAO and the LGBTQ+ community, providing a coordinated community response to address disproportionately high HIV and STI incidence rates in Jefferson County, Alabama.
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
30 January 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee.
05 January 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY® net product revenue for the fourth quarter and year ended December 31, 2022.
Grand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
31 October 2023
Long COVID study expanded across Europe
30 November 2023
Ethical, Regulatory, and Operational Considerations for Cell and Gene Therapy Research in Children
30 November 2023
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
29 November 2023
Imaging AI hogs the spotlight at RSNA, with debuts from GE, Siemens, Philips
29 November 2023